Items tagged with Treatment
Otsuka to advance development of novel TB compound (post)
Otsuka awarded grant to advance development of novel TB compound OPC-167832 with delamanid
ZeNix clinical trial announced (post)
NEW YORK (7 February, 2018) — TB Alliance has announced the start of a clinical trial of a three-drug regimen to treat extensively drug resistant tuberculosis (XDR-TB)—one of the deadliest forms of tuberculosis (TB)—and those with pre-XDR-TB and multi-drug resident TB (MDR-TB) whose prior treatment has failed or who have not tolerated their treatment.
Three more hospitals in India get approval to administer bedaquiline (post)
Apart from KEM, Nair Hospital, Sion Hospital and Govandi’s Shatabdi Hospital will be able to administer bedaquiline to drug-resistant tuberculosis patients.
Comprehensive care and support significantly boosts MDR-TB successful treatment completion (post)
A Taiwan program of comprehensive support and care centered on the needs of patients being treated for multidrug-resistant tuberculosis — at a cost of from $25,000 to $30,000 per patient, per year over the costs of medicines — substantially improved cure rates and drastically reduced rates of patients whose outcomes were unknown, according to a study reported in Clinical Infectious Diseases.
Unexpected toxicities identified with concomitant HIV, TB treatment use (post)
Combining dolutegravir with isoniazid plus rifapentine may lead to serious side effects, including flu-like syndrome and elevated transaminase levels. The findings come from a drug-drug interaction study conducted by researchers at the National Institute of Health and Colorado State University.
Promising MSF research highlights immense benefits, need for expanded use of DR-TB drug combination (post)
NEW YORK, FEBRUARY 14, 2018—New research published today in The Lancet Infectious Diseases journal by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) provides strong evidence that a combination of two new drugs for tuberculosis (TB)—the world’s leading infectious disease killer—could be used to treat drug-resistant (DR-TB) forms of the disease. These findings encourage the wider use of these medicines in combination for DR-TB patients worldwide.
Report of the WHO webinar for civil society and partners on TB guidelines development (post)
The World Health Organization (WHO) Global TB Programme convened a webinar on the WHO guideline development process, with a focus on guidelines for the management of multidrug-resistant TB (MDR-TB). The webinar was held on 27 February 2018, based on a request from civil society participants at a WHO meeting in January 2018 to discuss the process, format, and dissemination of WHO guidelines. The webinar was attended by more than 60 participants. Tereza Kasaeva, Director of the WHO Global TB Programme, opened the event and welcomed participants. The webinar was moderated by Haileyesus Getahun, Coordinator of TB/HIV and Community Engagement, Global TB Programme.
ViiV Healthcare announces dolutegravir data for the treatment of HIV/TB co-infection (post)
ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis
INSPIRING study results contribute to the extensive body of evidence for dolutegravir, the leading integrase strand transfer inhibitor, in diverse and hard to treat patient populations
Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin (post)
Plasma concentrations of tenofovir alafenamide AUC were decreased by 55% and intracellular tenofovir-diphosphate concentrations by 36% when given with rifampicin. But intracellular concentrations were still 76% higher than those with standard dose tenofovir disoproxil fumarate.
Higher rifampin doses safe for patients with pulmonary TB (post)
BOSTON — Results of a phase 2 randomized clinical trial show that up to twice the standard daily dose of rifampin was safe in patients with pulmonary tuberculosis. The findings suggest that TB therapy can be shortened using higher doses, which could potentially improve outcomes without increasing toxicity.
Page 37 of 108 · Total posts: 0
←First 36 37 38 Last→